TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7920748

Group type: EXPERIMENTAL
Intervention: GnRH analogue, goserelin (Zoladex), 3.6 mg/inj monthly for 6 months
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (20 women with normal menstrual cycles)
Number of subjects: 27
Study: 3183305

Group type: EXPERIMENTAL
Intervention: Scopolamine (anticholinergic)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scopolamine plus physostigmine (anticholinesterase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scopolamine plus methylphenidate (adrenergic)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31499227

Group type: EXPERIMENTAL
Intervention: Health coaching intervention with 10 live coaching sessions delivered virtually by health coaches using tablets.
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Health coaching intervention
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standardized health information via tablets
Number of subjects: 250
Study: 28596245

Group type: EXPERIMENTAL
Intervention: Computerised cognitive-behavioural therapy (cCBT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Psychiatric treatment as usual (TAU)
Number of subjects: 52
Study: 26545527

Group type: EXPERIMENTAL
Intervention: Yogurt with added whey protein (PSL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Chocolate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Biscuits
Number of subjects: 20
Study: 23319454

Group type: EXPERIMENTAL
Intervention: Modified Cognitive Behavioral Therapy (mCBT)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 59
Study: 21764662

Group type: EXPERIMENTAL
Intervention: High dose tirofiban (HDT)
Number of subjects: 1370

Group type: COMPARATOR
Intervention: Control (placebo or no HDT)
Number of subjects: 1370
Study: 19591158

Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair
Number of subjects: 8

Group type: COMPARATOR
Intervention: Open hernia repair
Number of subjects: 8
Study: 16999648

Group type: COMPARATOR
Intervention: Glyburide
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 502
Study: 12393605

Group type: EXPERIMENTAL
Intervention: TAD/HAM double induction, TAD consolidation, and either maintenance therapy or S-HAM consolidation
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Day 16 blasts (continuous variable)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Event-free survival (EFS)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Relapse-free survival (RFS)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Multivariate analyses for CR rate
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Multivariate analyses for OS
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Multivariate analyses for EFS
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Multivariate analyses for RFS
Number of subjects: 449
Study: 11004254

Group type: EXPERIMENTAL
Intervention: Photoastigmatic refractive keratectomy with the Summit Apex Plus excimer laser
Number of subjects: 56
Study: 8648777

Group type: EXPERIMENTAL
Intervention: 400 mg oral fleroxacin once daily
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 1397701

Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (60% of total energy from carbohydrates)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low-carbohydrate diet (35% of total energy from carbohydrates)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Euglycemic hyperinsulinemic glucose clamp study
Number of subjects: 8
Study: 6145727

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate
Number of subjects: 577

Group type: COMPARATOR
Intervention: No drug therapy (control)
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Phenothiazine-treated groups (chlorpromazine and fluphenazine)
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Phenothiazine-treated patients
Number of subjects: 577
Study: 31895286

Group type: EXPERIMENTAL
Intervention: Long Active Recovery (LAR - 8 minutes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long Passive Recovery (LPR - 8 minutes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short Passive Recovery (SPR - 2 minutes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short Active Recovery (SAR - 2 minutes)
Number of subjects: 0
Study: 31520897

Group type: EXPERIMENTAL
Intervention: apabetalone 100 mg orally twice daily
Number of subjects: 2425

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2425
Study: 30696670

Group type: EXPERIMENTAL
Intervention: Inhaler education programme with teach-to-goal placebo-device training
Number of subjects: 146

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 146
Study: 28964963

Group type: EXPERIMENTAL
Intervention: Local endometrial injury (scratch) performed in 40 patients
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (40 patients without local endometrial injury)
Number of subjects: 80
Study: 25855534

Group type: EXPERIMENTAL
Intervention: Visual stimuli that allowed early visual processing stages (Experiments 1-3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual stimuli that obstructed early visual processing stages (Experiments 1-3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Possible Necker cubes (Experiments 4 and 5)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Impossible Necker cubes (Experiments 4 and 5)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Facial muscle responses (zygomaticus activity; Experiments 3 and 7)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verbal preference ratings (Experiments 1, 2, and 4)
Number of subjects: 0
Study: 23924261

Group type: EXPERIMENTAL
Intervention: Aspirin (240 mg/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 21854144

Group type: EXPERIMENTAL
Intervention: Commitments to change (CTC) made immediately after the lecture
Number of subjects: 144

Group type: COMPARATOR
Intervention: Commitments to change (CTC) made 7 days post-lecture
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Commitments made by participants from either group
Number of subjects: 144
Study: 20008230

Group type: EXPERIMENTAL
Intervention: Fludarabine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bendamustine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel monoclonal antibodies targeting CD20, CD23, or CD40
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flavopiridol, Oblimersen, Lenalidomide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduced-intensity allogeneic progenitor cell transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New prognostic markers
Number of subjects: 0
Study: 17240066

Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 2

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 2
Study: 15520364

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 to 40 mg/d)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 to 45 mg/d)
Number of subjects: 246
Study: 11883741

Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg administered once daily via Turbuhaler
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9683002

Group type: EXPERIMENTAL
Intervention: MgSO4 (3 g MgSO4 between 2030 hours and 2100 hours, followed by 0.5 g MgSO4 per hour until 0700 hours)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MgSO4
Number of subjects: 10
Study: 8062317

Group type: EXPERIMENTAL
Intervention: Diltiazem XR (240 mg, then 480 mg after 4 weeks if DBP > 90 mm Hg)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Diltiazem XR
Number of subjects: 350

Group type: COMPARATOR
Intervention: Diltiazem XR and Placebo
Number of subjects: 350
Study: 3045726

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Combined tamoxifen and aminoglutethimide
Number of subjects: 105
Study: 29678370

Group type: EXPERIMENTAL
Intervention: 4 mg/kg octanoic acid (OA)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 26179823

Group type: EXPERIMENTAL
Intervention: Pictorial self‐adhesive prescriptions
Number of subjects: 54

Group type: COMPARATOR
Intervention: Handwritten drug charts
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Pictorial printed labels
Number of subjects: 54
Study: 26188642

Group type: EXPERIMENTAL
Intervention: LCPUFAs (1.4 g of eicosapentaenoic and docosahexaeonic acids)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: LCPUFAs
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 24307845

Group type: EXPERIMENTAL
Intervention: Enteric-coated alendronate (5 mg) and calcitriol (0.5 µg) combined drug (Maxmarvil)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Alendronate only
Number of subjects: 33
Study: 22194858

Group type: EXPERIMENTAL
Intervention: RYGB with omentectomy
Number of subjects: 21

Group type: COMPARATOR
Intervention: RYGB non-omentectomy
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: RYGB with and without omentectomy
Number of subjects: 21
Study: 19446459

Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 44

Group type: COMPARATOR
Intervention: Ordinary Sound
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Acoustic Environment Importance
Number of subjects: 44
Study: 16563996

Group type: EXPERIMENTAL
Intervention: Single-dose brachytherapy (12 Gy)
Number of subjects: 95
Study: 15262613

Group type: EXPERIMENTAL
Intervention: Transxiphoid approach for ASD/VSD repair
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Logistic model used in a prospective study
Number of subjects: 26
Study: 10718834

Group type: EXPERIMENTAL
Intervention: Combined stimulation with CRH (100 micrograms i.v.) plus desmopressin (10 micrograms i.v.) during BIPSS
Number of subjects: 34

Group type: COMPARATOR
Intervention: CRH stimulation alone (100 micrograms i.v.) during BIPSS
Number of subjects: 34

Group type: COMPARATOR
Intervention: CRH stimulation in oEAS patients
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Combined stimulation in oEAS patient
Number of subjects: 34
Study: 9327193

Group type: EXPERIMENTAL
Intervention: Quinapril (2.5 mg once-daily)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Captopril (6.25 mg twice-daily)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Quinapril and Captopril (both groups)
Number of subjects: 61
Study: 8096941

Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 282777
Study: 6942649

Group type: EXPERIMENTAL
Intervention: Vegetable leaves and stalks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole grains
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sucrose supplement
Number of subjects: 0
Study: 30383312

Group type: COMPARATOR
Intervention: Noninvasive brain stimulation (NIBS) over the primary sensorimotor missing hand cortex (S1/M1) during phantom hand movements.
Number of subjects: 0

Group type: COMPARATOR
Intervention: NIBS intervention
Number of subjects: 0
Study: 28390444

Group type: EXPERIMENTAL
Intervention: Exposure and response prevention for OCD
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Conscientiousness scores
Number of subjects: 46
Study: 26449137

Group type: EXPERIMENTAL
Intervention: Sodium nitrite
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 24044799

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 21077956

Group type: EXPERIMENTAL
Intervention: Continuous self-improvement intervention (n = 8)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Attention control management (n = 5)
Number of subjects: 15
Study: 19367517

Group type: EXPERIMENTAL
Intervention: Amputee Mobility Aid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pneumatic Post‐Amputation Aid
Number of subjects: 0
Study: 17971939

Group type: EXPERIMENTAL
Intervention: Initial stage group (44 cases)
Number of subjects: 148

Group type: COMPARATOR
Intervention: After initial stage group (104 cases)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Common type group (87 cases)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Severe type group (61 cases)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Unilobar lung involvement group (49 cases)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Bilobar lung involvement group (53 cases)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Diffuse lung involvement group (46 cases)
Number of subjects: 148
Study: 16789405

Group type: EXPERIMENTAL
Intervention: Structured cardiac rehabilitation program (CRP)
Number of subjects: 104

Group type: COMPARATOR
Intervention: General cardiology clinic (GC)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Planned coronary follow-up program (FUP)
Number of subjects: 104
Study: 14512699

Group type: EXPERIMENTAL
Intervention: 1% inspired isoflurane concentration (C(I)iso)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 2% inspired isoflurane concentration (C(I)iso)
Number of subjects: 16
Study: 10352053

Group type: EXPERIMENTAL
Intervention: New intravenous therapy protocol
Number of subjects: 219

Group type: COMPARATOR
Intervention: Old intravenous therapy protocol
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Nurses' judgments related to intravenous therapy initiation
Number of subjects: 219
Study: 8618811

Group type: EXPERIMENTAL
Intervention: rhuEPO treatment for 12 months
Number of subjects: 27

Group type: COMPARATOR
Intervention: non-EPO group (clinical monitoring)
Number of subjects: 27

Group type: COMPARATOR
Intervention: HD group (hemodialyzed patients with haematocrit > 30%)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 27
Study: 2202791

Group type: EXPERIMENTAL
Intervention: Doxorubicin (AC) for 2 months
Number of subjects: 2194

Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, and fluorouracil (CMF) for 6 months
Number of subjects: 2194

Group type: EXPERIMENTAL
Intervention: AC followed by IV CMF
Number of subjects: 2194

Group type: EXPERIMENTAL
Intervention: AC therapy
Number of subjects: 2194
Study: 6814757

Group type: EXPERIMENTAL
Intervention: V-PLAT (VM-26, cisplatin, and prednisone)
Number of subjects: 123

Group type: COMPARATOR
Intervention: V-HEX (VM-26, hexamethylmelamine, and prednisone)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: V-PLAT
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Both V-PLAT and V-HEX
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: VM-26 and hexamethylmelamine as single agents
Number of subjects: 123
Study: 30590411

Group type: EXPERIMENTAL
Intervention: Folic Acid (400 or 800 μg per day)
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Creatine (3 g per day)
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Folic Acid (800 µg)
Number of subjects: 622

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 622
Study: 28655901

Group type: EXPERIMENTAL
Intervention: Chronic sleep restriction (3 weeks, 5 nights of 4 hours sleep followed by 2 nights of 8 hours sleep)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rested state (3 weeks of 8 hours time in bed per night)
Number of subjects: 0
Study: 25994905

Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBV)
Number of subjects: 25
Study: 23364814

Group type: EXPERIMENTAL
Intervention: Cocoa polyphenols (500 mg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Cocoa polyphenols (250 mg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (0 mg)
Number of subjects: 72
Study: 21854625

Group type: EXPERIMENTAL
Intervention: Esmolol 1 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 60
Study: 18188136

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR) exercise program
Number of subjects: 64
Study: 16564292

Group type: EXPERIMENTAL
Intervention: Phosphorylcholine-coated CPB system
Number of subjects: 28

Group type: COMPARATOR
Intervention: Uncoated CPB system (Control)
Number of subjects: 28
Study: 12656907

Group type: EXPERIMENTAL
Intervention: Colchicine 1 mg every 12 hours plus Vitamin E 600 mg/day for 6 months
Number of subjects: 45

Group type: COMPARATOR
Intervention: Ibuprofen 400 mg/day for 6 months
Number of subjects: 45
Study: 11252642

Group type: EXPERIMENTAL
Intervention: Lithium therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valproate and carbamazepine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nimodipine and related dihydropyridine calcium channel blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lamotrigine, gabapentin, topiramate, atypical neuroleptics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unimodal antidepressants
Number of subjects: 0
Study: 8820469

Group type: EXPERIMENTAL
Intervention: Dolasetron mesylate 25, 50, 100, 150, or 200 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 1595343

Group type: EXPERIMENTAL
Intervention: Alfentanil 100 micrograms/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 24
Study: 6475177

Group type: EXPERIMENTAL
Intervention: teopranitol (KC 046) 0.04 mg/kg body weight
Number of subjects: 10

Group type: COMPARATOR
Intervention: untreated patients with coronary heart disease
Number of subjects: 10
Study: 31586022

Group type: EXPERIMENTAL
Intervention: Romiplostim (weekly subcutaneous injections)
Number of subjects: 31
Study: 29577710

Group type: EXPERIMENTAL
Intervention: Scaling and root planing with Low Level Laser Therapy (LLLT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Scaling and root planing
Number of subjects: 30
Study: 27354368

Group type: EXPERIMENTAL
Intervention: 15 µg GI.1 VLP and 50 µg GII.4 VLP (15/50 formulation)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: 50 µg GI.1 VLP and 50 µg GII.4 VLP (50/50 formulation)
Number of subjects: 454

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 454
Study: 24573567

Group type: EXPERIMENTAL
Intervention: Dual-source high-pitch CTA
Number of subjects: 20

Group type: COMPARATOR
Intervention: Single-source standard-pitch CTA
Number of subjects: 20
Study: 23013243

Group type: EXPERIMENTAL
Intervention: Maternal T2D genetic risk score (T2DGRS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal and offspring fasting glucose genetic risk score (FGGRS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fasting glucose plasma measurements
Number of subjects: 0
Study: 20562074

Group type: EXPERIMENTAL
Intervention: Biolimus eluting stent (BES)
Number of subjects: 1707

Group type: COMPARATOR
Intervention: Sirolimus eluting stent (SES)
Number of subjects: 1707
Study: 17594068

Group type: EXPERIMENTAL
Intervention: Endovascular treatment for abdominal aneurysms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Open surgery for abdominal aneurysms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New endovascular procedures for thoracic aorta
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endovascular procedures
Number of subjects: 0
Study: 15766301

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 369

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 369
Study: 11295900

Group type: EXPERIMENTAL
Intervention: Exercises
Number of subjects: 27

Group type: COMPARATOR
Intervention: Back schools
Number of subjects: 27

Group type: COMPARATOR
Intervention: Lumbar supports
Number of subjects: 27

Group type: COMPARATOR
Intervention: Ergonomic interventions
Number of subjects: 27

Group type: COMPARATOR
Intervention: Risk factor modification
Number of subjects: 27
Study: 9589514

Group type: EXPERIMENTAL
Intervention: Membrane phospholipid hypothesis as a biochemical basis for schizophrenia
Number of subjects: 0
Study: 7941199

Group type: EXPERIMENTAL
Intervention: General anesthesia and caudal nerve block
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: General anesthesia and local nerve block
Number of subjects: 77

Group type: COMPARATOR
Intervention: General anesthesia alone
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Caudal nerve block
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Local nerve block
Number of subjects: 77
Study: 2975095

Group type: EXPERIMENTAL
Intervention: Isradipine (0.5 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nifedipine (2 mg)
Number of subjects: 30
Study: 29298255

Group type: EXPERIMENTAL
Intervention: Suture Button (SB)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Single Syndesmotic Screw (SS)
Number of subjects: 97
Study: 28774339

Group type: EXPERIMENTAL
Intervention: Culturally appropriate depression education intervention
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard education
Number of subjects: 150
Study: 26635906

Group type: EXPERIMENTAL
Intervention: Methylation classifier comprised of 22 CpG islands
Number of subjects: 226

Group type: COMPARATOR
Intervention: Cancer-free control subjects
Number of subjects: 226
Study: 23841267

Group type: EXPERIMENTAL
Intervention: Qingjie Tongluo Recipe (QTR) plus external washing of Chinese herbs plus external dressing by herbs
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine aseptic external dressing
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (after treatment)
Number of subjects: 60
Study: 20929990

Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Triple therapy (rosiglitazone, metformin, and any insulin)
Number of subjects: 371
Study: 19301513

Group type: EXPERIMENTAL
Intervention: Test Dentifrice (0.3% triclosan/2.0% PVM/MA copolymer/sodium fluoride in a 17% dual silica base)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Positive Control Dentifrice (0.3% triclosan/2.0% PVM/MA copolymer/sodium fluoride in a 10% high-cleaning silica base)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Negative Control Dentifrice (0.243% sodium fluoride in a regular silica base)
Number of subjects: 33